Grail, Inc. (NASDAQ:GRAL - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $36.33, but opened at $34.52. Grail shares last traded at $37.45, with a volume of 326,979 shares changing hands.
Analyst Ratings Changes
Several equities analysts recently weighed in on GRAL shares. Morgan Stanley initiated coverage on shares of Grail in a report on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 price objective on the stock. Wolfe Research initiated coverage on shares of Grail in a research note on Friday, November 15th. They issued a "peer perform" rating for the company.
View Our Latest Analysis on Grail
Grail Stock Down 1.7 %
The company's 50 day simple moving average is $30.64 and its 200 day simple moving average is $20.84.
Grail (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55. The firm had revenue of $38.25 million during the quarter, compared to the consensus estimate of $35.33 million. On average, equities research analysts forecast that Grail, Inc. will post -15.15 EPS for the current fiscal year.
Institutional Investors Weigh In On Grail
Large investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC bought a new stake in shares of Grail during the fourth quarter worth $26,000. State of Tennessee Department of Treasury bought a new stake in shares of Grail during the fourth quarter worth $28,000. Lindbrook Capital LLC bought a new stake in shares of Grail during the fourth quarter worth $28,000. Sterling Capital Management LLC bought a new stake in shares of Grail during the fourth quarter worth $29,000. Finally, Wellington Shields Capital Management LLC bought a new stake in shares of Grail during the fourth quarter worth $33,000.
About Grail
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Further Reading
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
